Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring because their cancer is more likely to recur.
This article was originally published on MedicalXpress.com

